Skip to content

GLUE

Monte Rosa Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$23.48-4.40%

Price as of Jul 20, 2026

GLUE news

Monte Rosa Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 18,025 shares of Monte Rosa Therapeutics common stock

    Globe Newswire ·